Drug Development Pipeline
Dornase Alfa (Pulmozyme®)
Dornase alfa (Pulmozyme®) is an inhaled medication that thins and loosens mucus in the airways of people with CF.
A Phase 3 clinical trial showed improvement in lung function and reduction in pulmonary exacerbations. It received FDA approval in 1993.
The program was sponsored by Genentech, Inc and the Cystic Fibrosis Foundation.
Recent Dornase Alfa (Pulmozyme®) Studies
Completed with Results
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More